Evercore ISI initiated coverage of DexCom (DXCM) with an In Line rating and $68 price target Though DexCom serves the “large and vastly underpenetrated” diabetes market, the firm’s In Line rating reflects its belief that product quality and manufacturing issues and competitive threats will continue to disrupt the company’s share gain opportunity through 2026, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: